RhumbLine Advisers
GLUE icon

RhumbLine Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History

RhumbLine Advisers’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
94,593
+18,185
+24% +$344K ﹤0.01% 1871
2026
Q1 		$1.26M Buy
76,408
+14,549
+24% +$278K ﹤0.01% 2080
2025
Q4 		$970K Sell
61,859
-2,087
-3% -$28.1K ﹤0.01% 2243
2025
Q3 		$474K Buy
63,946
+361
+0.6% +$1.91K ﹤0.01% 2732
2025
Q2 		$287K Buy
63,585
+1,346
+2% +$6K ﹤0.01% 3010
2025
Q1 		$289K Buy
62,239
+448
+0.7% +$2.75K ﹤0.01% 2910
2024
Q4 		$429K Buy
61,791
+9,323
+18% +$70K ﹤0.01% 2768
2024
Q3 		$278K Buy
52,468
+4,543
+9% +$22.9K ﹤0.01% 3066
2024
Q2 		$179K Buy
47,925
+1,372
+3% +$7K ﹤0.01% 3284
2024
Q1 		$328K Buy
46,553
+1,193
+3% +$7.08K ﹤0.01% 2936
2023
Q4 		$256K Sell
45,360
-243
-0.5% -$953 ﹤0.01% 3060
2023
Q3 		$218K Buy
45,603
+578
+1% +$3.72K ﹤0.01% 3116
2023
Q2 		$308K Sell
45,025
-1,148
-2% -$7.42K ﹤0.01% 2997
2023
Q1 		$360K Buy
46,173
+2,324
+5% +$16.2K ﹤0.01% 2556
2022
Q4 		$334K Buy
43,849
+887
+2% +$7.39K ﹤0.01% 2636
2022
Q3 		$351K Buy
42,962
+2,412
+6% +$22.2K ﹤0.01% 2654
2022
Q2 		$392K Buy
40,550
+16,358
+68% +$164K ﹤0.01% 2620
2022
Q1 		$339K Buy
+24,192
New +$336K ﹤0.01% 2597
2021
Q4 		– Sell
-9,233
Closed -$206K – 3008
2021
Q3 		$206K Buy
+9,233
New +$265K ﹤0.01% 2906

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's GLUE Position: Q2 2026 in Review

RhumbLine Advisers increased its Monte Rosa Therapeutics (GLUE) stake by 24% in Q2 2026, buying an estimated $344K and bringing the position to 94,593 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

RhumbLine Advisers first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • RhumbLine Advisers held 94,593 shares of Monte Rosa Therapeutics worth $2.29M as of Q2 2026.
  • RhumbLine Advisers bought 18,185 Monte Rosa Therapeutics shares in Q2 2026, an estimated $344K.
  • Monte Rosa Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1871 holding.
  • RhumbLine Advisers first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.